126 related articles for article (PubMed ID: 38761648)
21. MicroRNA expression might predict prognosis of epithelial hepatoblastoma.
Gyugos M; Lendvai G; Kenessey I; Schlachter K; Halász J; Nagy P; Garami M; Jakab Z; Schaff Z; Kiss A
Virchows Arch; 2014 Apr; 464(4):419-27. PubMed ID: 24570391
[TBL] [Abstract][Full Text] [Related]
22. FOXM1 confers acquired cisplatin resistance in breast cancer cells.
Kwok JM; Peck B; Monteiro LJ; Schwenen HD; Millour J; Coombes RC; Myatt SS; Lam EW
Mol Cancer Res; 2010 Jan; 8(1):24-34. PubMed ID: 20068070
[TBL] [Abstract][Full Text] [Related]
23. PIM kinases mediate resistance to cisplatin chemotherapy in hepatoblastoma.
Marayati R; Stafman LL; Williams AP; Bownes LV; Quinn CH; Aye JM; Stewart JE; Yoon KJ; Anderson JC; Willey CD; Beierle EA
Sci Rep; 2021 Mar; 11(1):5984. PubMed ID: 33727604
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of Bcl-2 and Bcl-X enhances chemotherapy sensitivity in hepatoblastoma cells.
Lieber J; Kirchner B; Eicher C; Warmann SW; Seitz G; Fuchs J; Armeanu-Ebinger S
Pediatr Blood Cancer; 2010 Dec; 55(6):1089-95. PubMed ID: 20680965
[TBL] [Abstract][Full Text] [Related]
25. Hepatoblastoma presenting with lung metastases: treatment results of the first cooperative, prospective study of the International Society of Paediatric Oncology on childhood liver tumors.
Perilongo G; Brown J; Shafford E; Brock P; De Camargo B; Keeling JW; Vos A; Philips A; Pritchard J; Plaschkes J
Cancer; 2000 Oct; 89(8):1845-53. PubMed ID: 11042582
[TBL] [Abstract][Full Text] [Related]
26. Knockdown of circ_0006528 Suppresses Cell Proliferation, Migration, Invasion, and Adriamycin Chemoresistance via Regulating the miR-1236-3p/CHD4 Axis in Breast Cancer.
Hao J; Du X; Lv F; Shi Q
J Surg Res; 2021 Apr; 260():104-115. PubMed ID: 33333383
[TBL] [Abstract][Full Text] [Related]
27. Increased expression of survivin in hepatoblastoma after chemotherapy.
Uehara S; Oue T; Kawatsu M; Nara K; Fukuzawa M
Eur J Pediatr Surg; 2013 Oct; 23(5):400-4. PubMed ID: 23444076
[TBL] [Abstract][Full Text] [Related]
28. Risk-adapted treatment for childhood hepatoblastoma. final report of the second study of the International Society of Paediatric Oncology--SIOPEL 2.
Perilongo G; Shafford E; Maibach R; Aronson D; Brugières L; Brock P; Childs M; Czauderna P; MacKinlay G; Otte JB; Pritchard J; Rondelli R; Scopinaro M; Staalman C; Plaschkes J;
Eur J Cancer; 2004 Feb; 40(3):411-21. PubMed ID: 14746860
[TBL] [Abstract][Full Text] [Related]
29. Aberrant expression of cancer stem cell markers (CD44, CD90, and CD133) contributes to disease progression and reduced survival in hepatoblastoma patients: 4-year survival data.
Bahnassy AA; Fawzy M; El-Wakil M; Zekri AR; Abdel-Sayed A; Sheta M
Transl Res; 2015 Mar; 165(3):396-406. PubMed ID: 25168019
[TBL] [Abstract][Full Text] [Related]
30. Pretreatment prognostic factors and treatment results in children with hepatoblastoma: a report from the German Cooperative Pediatric Liver Tumor Study HB 94.
Fuchs J; Rydzynski J; Von Schweinitz D; Bode U; Hecker H; Weinel P; Bürger D; Harms D; Erttmann R; Oldhafer K; Mildenberger H;
Cancer; 2002 Jul; 95(1):172-82. PubMed ID: 12115331
[TBL] [Abstract][Full Text] [Related]
31. Utility of PAS and β-catenin staining in histological categorisation and prediction of prognosis of hepatoblastomas.
Bera G; Das RN; Roy P; Ghosh R; Islam N; Mishra PK; Chatterjee U
Pediatr Surg Int; 2017 Sep; 33(9):961-970. PubMed ID: 28631020
[TBL] [Abstract][Full Text] [Related]
32. High tricellulin expression is associated with better survival in human hepatoblastoma.
Schlachter K; Gyugos M; Halász J; Lendvai G; Baghy K; Garami M; Gyöngyösi B; Schaff Z; Kiss A
Histopathology; 2014 Nov; 65(5):631-41. PubMed ID: 24735023
[TBL] [Abstract][Full Text] [Related]
33. Connectivity map identifies HDAC inhibition as a treatment option of high-risk hepatoblastoma.
Beck A; Eberherr C; Hagemann M; Cairo S; Häberle B; Vokuhl C; von Schweinitz D; Kappler R
Cancer Biol Ther; 2016 Nov; 17(11):1168-1176. PubMed ID: 27635950
[TBL] [Abstract][Full Text] [Related]
34. Upfront window vincristine/irinotecan treatment of high-risk hepatoblastoma: A report from the Children's Oncology Group AHEP0731 study committee.
Katzenstein HM; Furman WL; Malogolowkin MH; Krailo MD; McCarville MB; Towbin AJ; Tiao GM; Finegold MJ; Ranganathan S; Dunn SP; Langham MR; McGahren ED; Rodriguez-Galindo C; Meyers RL
Cancer; 2017 Jun; 123(12):2360-2367. PubMed ID: 28211941
[TBL] [Abstract][Full Text] [Related]
35. FOXM1 Is a Novel Molecular Target of AFP-Positive Hepatocellular Carcinoma Abrogated by Proteasome Inhibition.
Li R; Okada H; Yamashita T; Nio K; Chen H; Li Y; Shimakami T; Takatori H; Arai K; Sakai Y; Yamashita T; Mizukoshi E; Honda M; Kaneko S
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35955438
[TBL] [Abstract][Full Text] [Related]
36. Sarcomatoid hepatocellular carcinoma with hepatoblastoma-like features in an adult.
Cho MS; Lee SN; Sung SH; Han WS
Pathol Int; 2004 Jun; 54(6):446-50. PubMed ID: 15144405
[TBL] [Abstract][Full Text] [Related]
37. Hepatocellular malignant neoplasm, NOS: a clinicopathological study of 11 cases from a single institution.
Zhou S; Venkatramani R; Gupta S; Wang K; Stein JE; Wang L; Mascarenhas L
Histopathology; 2017 Nov; 71(5):813-822. PubMed ID: 28660626
[TBL] [Abstract][Full Text] [Related]
38. METase/lncRNA HULC/FoxM1 reduced cisplatin resistance in gastric cancer by suppressing autophagy.
Xin L; Zhou Q; Yuan YW; Zhou LQ; Liu L; Li SH; Liu C
J Cancer Res Clin Oncol; 2019 Oct; 145(10):2507-2517. PubMed ID: 31485766
[TBL] [Abstract][Full Text] [Related]
39. Successful treatment of doxorubicin and cisplatin resistant hepatoblastoma in a child with Beckwith-Wiedemann syndrome with high dose acetaminophen and N-acetylcysteine rescue.
Kobrinsky NL; Sjolander DE; Goldenberg JA; Ortmeier TC
Pediatr Blood Cancer; 2005 Aug; 45(2):222-5. PubMed ID: 15770640
[TBL] [Abstract][Full Text] [Related]
40. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
